Zacks: Analysts Anticipate Quanterix Corp (QTRX) to Announce -$0.30 Earnings Per Share

Equities research analysts expect Quanterix Corp (NASDAQ:QTRX) to report ($0.30) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Quanterix’s earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.29). The firm is scheduled to report its next earnings report after the market closes on Wednesday, March 14th.

On average, analysts expect that Quanterix will report full-year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.20) to ($1.17). For the next year, analysts expect that the business will report earnings of ($0.93) per share, with EPS estimates ranging from ($0.96) to ($0.90). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Quanterix.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They issued an “overweight” rating for the company. Leerink Swann assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $27.00 price objective for the company. Cowen assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They issued an “outperform” rating for the company. Finally, BTIG Research assumed coverage on shares of Quanterix in a report on Tuesday, January 2nd. They issued a “buy” rating and a $26.00 price objective for the company.

Shares of Quanterix (QTRX) opened at $18.67 on Friday. Quanterix has a 1-year low of $15.56 and a 1-year high of $24.81.

In related news, insider E Kevin Hrusovsky bought 34,000 shares of the stock in a transaction on Monday, December 11th. The stock was bought at an average price of $15.00 per share, with a total value of $510,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Venture Fund Viii Overage Arch bought 266,000 shares of the stock in a transaction on Monday, December 11th. The shares were bought at an average cost of $15.00 per share, with a total value of $3,990,000.00. The disclosure for this purchase can be found here. Insiders purchased 500,000 shares of company stock valued at $7,500,000 in the last three months.

A number of hedge funds have recently made changes to their positions in the business. Landscape Capital Management L.L.C. purchased a new position in Quanterix during the fourth quarter worth about $720,000. Goldman Sachs Group Inc. purchased a new position in Quanterix during the fourth quarter worth about $873,000. Opaleye Management Inc. purchased a new position in Quanterix during the fourth quarter worth about $1,395,000. Perceptive Advisors LLC purchased a new position in Quanterix during the fourth quarter worth about $3,637,000. Finally, Platinum Investment Management Ltd. purchased a new position in Quanterix during the fourth quarter worth about $3,757,000. 42.39% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Quanterix Corp (QTRX) to Announce -$0.30 Earnings Per Share” was published by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://theenterpriseleader.com/2018/04/02/zacks-analysts-anticipate-quanterix-corp-qtrx-to-announce-0-30-earnings-per-share.html.

About Quanterix

Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply